Douglas Hanahan

Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland.

Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY.

Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland.

Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY.

Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY.

Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland.

Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland.

Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon.